Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to decipher a 300-page biopharma filing packed with clinical endpoints and FDA jargon can stall even seasoned analysts. Madrigal Pharmaceuticals鈥� SEC documents are no exception: every 10-K details Rezdiffra鈥檚 trial design, while 8-Ks flag pivotal data releases that can move the stock overnight. If you have searched for 鈥淢adrigal Pharmaceuticals SEC filings explained simply,鈥� you know the challenge.
Stock Titan cuts through that complexity. Our AI reads each Madrigal Pharmaceuticals quarterly earnings report 10-Q filing, highlights cash-runway updates, and links them to ongoing MAESTRO studies. Need fast context on a sudden press release? We deliver Madrigal Pharmaceuticals 8-K material events explained in plain English within minutes of EDGAR posting. AG真人官方-time alerts surface Madrigal Pharmaceuticals Form 4 insider transactions, so you can follow executive stock trades ahead of regulatory milestones. You will also find the annual report鈥�Madrigal Pharmaceuticals annual report 10-K simplified鈥攁nd an easy path to the Madrigal Pharmaceuticals proxy statement executive compensation that breaks down R&D-driven pay packages.
Whether you are monitoring Madrigal Pharmaceuticals insider trading Form 4 transactions, comparing Phase 3 expenses line-by-line, or seeking a concise Madrigal Pharmaceuticals earnings report filing analysis, our platform equips you to act decisively. AI-powered summaries, expert tagging, and comprehensive coverage of every form鈥�10-K, 10-Q, 8-K, S-3, plus Madrigal Pharmaceuticals executive stock transactions Form 4 in real time鈥攎ean fewer hours lost and more insights gained. Start understanding Madrigal Pharmaceuticals SEC documents with AI instead of wrestling with them.
AIM ImmunoTech (AIM) is conducting a Rule 424(b)(5) best-efforts offering of up to 2 million Units at $4.00 each, composed of one share (or pre-funded warrant) plus one Class E (5-yr) and one Class F (18-mo) warrant, for $8.0 m gross / ~$7.1 m net proceeds after 7% placement fee and expenses. Post-deal share count could rise from 764,188 to 2,764,188 (no warrant exercise), producing immediate dilution of $3.63/share. A further 100 k placement-agent warrants will be issued at 110% of the offer price.
Funds are earmarked (illustrative 100% raise) for:
- 37% payment of outstanding & future payables
- 32% clinical programs (Ampligen cancer, ME/CFS, Post-COVID, antiviral and vaccine adjuvant studies)
- 26% working capital
- 5% manufacturing
The company has a stockholders鈥� deficit of 鈭�$3.9 m (3/31/25) and $2.2 m cash. AIM is non-compliant with NYSE American鈥檚 $6 m equity rule; a plan to regain compliance must succeed by 11 Jun 2026 or shares risk delisting. A 1-for-100 reverse split became effective 12 Jun 2025 to restore trading on NYSE American.
Recent financing includes a $310 k unsecured bridge note due Oct-2025 and a prior $3.3 m Streeterville note (matures Feb-2026). The prospectus emphasises going-concern risk, absence of escrow/minimum raise, limited warrant liquidity and heavy potential dilution.
Madrigal Pharmaceuticals (MDGL) filed an 8-K disclosing a new $500 million senior secured credit facility arranged by Blue Owl funds on 17 Jul 2025. The package consists of (i) a $350 million initial term loan funded at closing, (ii) $150 million in delayed-draw commitments available through 31 Dec 2027, and (iii) an uncommitted $250 million incremental accordion. All borrowings mature on 17 Jul 2030 and are guaranteed by subsidiaries, with a first-priority lien on substantially all company assets.
Key terms & implications
- Interest options: Base rate (鈮�2.0%) + 3.75% or 3-mo Term SOFR (鈮�1.0%) + 4.75%; interest payable quarterly.
- Prepayment allowed at any time; maximum make-whole/penalty of 3%.
- Covenants: minimum $100 million unrestricted cash, customary affirmative/negative covenants, and change-of-control default.
- Proceeds repaid the May 2022 Hercules facility, retiring $121.6 million (principal $115 million plus interest/fees) and releasing all related liens.
- Facility boosts liquidity for clinical, regulatory and commercial plans while increasing leverage, incurring high-single-digit effective cost of capital and granting lenders tight collateral and covenant protection.
FAQ
What is the current stock price of Madrigal Pharmac (MDGL)?
What is the market cap of Madrigal Pharmac (MDGL)?
What is the core focus of Madrigal Pharmaceuticals?
What is Rezdiffra and how does it work?
How does Madrigal demonstrate its clinical and scientific expertise?
What sets Madrigal apart in the competitive landscape?
How does the company support patient access to its therapy?
What regulatory milestones has Madrigal achieved?
What future research directions is Madrigal pursuing?
How does Madrigal contribute to the broader understanding of liver disease?
